Human ageing is determined by degenerative alterations and processes with different manifestations such as gradual organ dysfunction, tissue function loss, increased population of aged (senescent) cells, incapability of maintaining homeostasis and reduced repair capacity, which collectively lead to an increased risk of diseases and death. The inhibitors of HMG-CoA reductase (statins) are the most widely used lipid-lowering agents, which can reduce cardiovascular morbidity and mortality. Accumulating evidence has documented several pleiotropic effects of statins in addition to their lipid-lowering properties. Recently, several studies have highlighted that statins may have the potential to delay the ageing process and inhibit the onset of senescence. In this review, we focused on the anti-ageing mechanisms of statin drugs and their effects on cardiovascular and non-cardiovascular diseases.

Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms

Bo S.;
2020-01-01

Abstract

Human ageing is determined by degenerative alterations and processes with different manifestations such as gradual organ dysfunction, tissue function loss, increased population of aged (senescent) cells, incapability of maintaining homeostasis and reduced repair capacity, which collectively lead to an increased risk of diseases and death. The inhibitors of HMG-CoA reductase (statins) are the most widely used lipid-lowering agents, which can reduce cardiovascular morbidity and mortality. Accumulating evidence has documented several pleiotropic effects of statins in addition to their lipid-lowering properties. Recently, several studies have highlighted that statins may have the potential to delay the ageing process and inhibit the onset of senescence. In this review, we focused on the anti-ageing mechanisms of statin drugs and their effects on cardiovascular and non-cardiovascular diseases.
2020
58
101024
101035
http://www.elsevier.com/locate/arr
klotho; RhoA; Senescence-associated secretory phenotype; Sirtuin-1; Telomerase
Bahrami A.; Bo S.; Jamialahmadi T.; Sahebkar A.
File in questo prodotto:
File Dimensione Formato  
Blinded Man R1 SB.docx

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 221.8 kB
Formato Microsoft Word XML
221.8 kB Microsoft Word XML   Visualizza/Apri   Richiedi una copia
Blinded Man R1 SB.pdf

Open Access dal 31/01/2021

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 445.62 kB
Formato Adobe PDF
445.62 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1739573
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 50
social impact